Nebulized Treprostinil Preserved IPF Lung Function
Phase 3 trial results show significant reductions in clinical worsening and acute exacerbations for patients with idiopathic pulmonary fibrosis (IPF).
Tag: pulmonary fibrosis and IPF
All
Latest
Nebulized Treprostinil Preserved IPF Lung Function
Phase 3 trial results show significant reductions in clinical worsening and acute exacerbations for patients with idiopathic pulmonary fibrosis (IPF).
Read More
FDA Approves IPF Generic Nintedanib
Dexcel Pharma USA will launch nintedanib capsules for patients with progressive lung disease following final regulatory approval.
Read More
Deupirfenidone May Stabilize IPF Lung Function
Data from the Phase 2b ELEVATE IPF trial suggest deupirfenidone maintains efficacy while offering a favorable safety and tolerability profile.
Read More
Inhaled Treprostinil Improves IPF Lung Function
Results from the TETON-1 study show nebulized Treprostinil (Tyvaso) met its primary endpoint, demonstrating a significant increase in IPF lung function compared to placebo.
Read More
Inhaled Pirfenidone May Stabilize Lung Fibrosis Scores
More than 70% of IPF patients receiving inhaled pirfenidone achieved stabilization or improvement in fibrosis scores at 24 weeks.
Read More
FDA, European Commission Grant Orphan Drug Designation for New IPF Treatment
Deupirfenidone showed a slower rate of lung function decline compared to existing therapies in a...
Read More
Lung Comorbidities Influence ILD Risk in Rheumatoid Arthritis
When comorbidity burden was assessed using the Rheumatic Disease Comorbidity Index (RDCI), higher scores were significantly associated with ILD development.
Read More
Positive Preclinical Data for IPF Drug
Thykamine showed statistically significant reductions in lung fibrosis, inflammation, and collagen-related gene expression in a bleomycin-induced pulmonary fibrosis mouse model.
Read More
Reduced Mortality in IPF Patients Using ACE Inhibitors
ACE inhibitor therapy correlated with reduced all-cause mortality in idiopathic pulmonary fibrosis patients, but not in COPD patients using ACE inhibitors.
Read More
Pulmonary Rehab Increased IPF Brain Oxygenation
Long-term pulmonary rehab led to higher VO2 peak, greater peak workload, longer exercise duration, and increased daily physical activity in patients with idiopathic pulmonary fibrosis (IPF).
Read More
FDA Approves Jascayd/Nerandomilast for Progressive Pulmonary Fibrosis
The US FDA has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis (PPF) in adults, according to Boehringer Ingelheim.
Read More
Researchers Test Possible IPF Therapeutic
A first-of-its-kind study will investigate diethyl succinate (DES) as a potential therapeutic for patients with idiopathic pulmonary fibrosis.
Read More
Jascayd/Nerandomilast Slowed FVC Decline in IPF
Addition of Nerandomilast (Jascayd) to a treatment regimen for patients receiving standard of care therapy for idiopathic pulmonary fibrosis may slow disease progression.
Read More
FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis
The US FDA approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis (IPF), the first new therapy approved in more than 10 years for IPF.
Read More
Positive Data for Nerandomilast in IPF/PPF
Boehringer Ingelheim revealed new data from two Phase 3 clinical trials on Nerandomilast, an investigational orally-administered drug candidate for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).
Read More
Group Singing Program Improved Lung Disease Symptoms
A weekly 90-minute online group singing session delivered for 12 weeks over Zoom was associated with improved quality of life in patients with COPD or interstitial lung disease.
Read MoreIL-10 Protein Plays Role in Pulmonary Fibrosis, Bronchiolitis
A small protein called IL-10 is critical for preventing lung inflammation and associated diseases like pulmonary fibrosis and bronchiolitis.
Read More
Prioritizing Prevention of Chronic Respiratory Diseases
ERS leaders are calling for health systems to prioritize and integrate the care of chronic respiratory diseases (CRDs) across Europe.
Read More
PF Patients Offered Lung Health Navigators Through Lung Association Program
To kickoff Pulmonary Fibrosis Awareness Month, the American Lung Association launched a new educational program that includes lung health navigators to support PF patients and families.
Read More
New Pulmonary Fibrosis Research Highlights Nerve-Fibroblast Interactions
New pulmonary fibrosis research highlights nerve-fibroblast interactions, showing that blocking alpha-1 adrenoreceptor signaling between sympathetic nerves and myofibroblasts mitigates lung fibrosis in both animal models and human tissue.
Read More
Studies Suggest Peptide May Benefit Idiopathic Pulmonary Fibrosis Patients
Two posters presented at ATS 2025 offered data on Rein Therapeutics’ novel peptide LTI-03’s potential clinical value for idiopathic pulmonary fibrosis patients.
Read More
Cancer Drug May Have Applications for Pulmonary Fibrosis
An FDA-approved cancer drug may help the immune system clear out damaged cells that cause the lung scarring, potentially restoring lung function in patients with pulmonary fibrosis.
Read More
Immune Cell Networks Drive Pulmonary Fibrosis
Networks of misplaced immune cells drive idiopathic pulmonary fibrosis — a discovery that may create a pathway to new treatments.
Read More
Surprisingly, Post-COVID-19 Pulmonary Fibrosis Tends to Resolve
Pulmonary fibrosis caused by severe COVID-19 shows a surprising tendency to resolve, offering new insights that may inform treatments for non-resolving forms of the disease.
Read More